Meta-analysis · Front Cardiovasc Med 2026
PCSK9 vs statin monotherapy meta-analysis
The lipid lowering efficacy of PCSK9 inhibitors alone vs. statins alone: a meta-analysis.
The bottom line
In patients who cannot tolerate statins, PCSK9 inhibitor monotherapy lowers LDL-C, ApoB, and raises HDL-C more than high-intensity statin monotherapy, though it is less effective at lowering triglycerides.
Primary lipid endpoint metUS status: Not applicable
At a glance
- Medicine
- PCSK9 inhibitor monotherapy (in statin-intolerant patient subgroups from PCSK9i vs. control RCTs)
- Compared with
- High-intensity statin monotherapy (atorvastatin 40 or 80 mg daily or rosuvastatin 20 or 40 mg daily) vs. control
- People
- 20,369
- Who took part
- Patients in RCTs of PCSK9i monotherapy (predominantly due to total statin intolerance) vs. patients in RCTs of high-intensity statin monotherapy; 5 trials (766 patients) for PCSK9is and 49 trials (19,603 patients) for statins; mean age 57.5±5.1 (PCSK9i) vs 60.2±2.3 (statin) years, women 54.3% vs 39.9%
- Design
- Meta-analysis of RCTs, PRISMA-adherent, comparing PCSK9i monotherapy subgroups vs. high-intensity statin monotherapy trials
- Follow-up
- ''
- Main question
- Mean percent change in serum LDL-C
Main result
PCSK9is showed significantly greater reductions in LDL-C compared to all high-intensity statin regimens combined (-52.4% vs. -46.6%, p = 0.03)
Effect on LDL cholesterol
PCSK9i: -52.4% vs. statins: -46.6% (p = 0.03)
Other results
Statin agent subgroup analysis found PCSK9is were superior to atorvastatin and comparable to rosuvastatin in increasing HDL-C and reducing LDL-C, ApoB, and TC, and inferior to atorvastatin and rosuvastatin in reducing TG.
Safety
''
In the trial's own words
“Compared to all high-intensity statin regimens combined, PCSK9is showed significantly greater reductions in LDL-C (-52.4% vs. -46.6%, p = 0.03), ApoB (-43.3% vs. -32.8%, p = 0.004), and increases in HDL-C (8.0% vs. 4.4%, p = 0.02).”
Quoted from the abstract of Front Cardiovasc Med 2026, checked word for word against PubMed. PubMed 41783026 · Full paper (DOI)
Common questions
What did the PCSK9 vs statin monotherapy meta-analysis trial find?
In patients who cannot tolerate statins, PCSK9 inhibitor monotherapy lowers LDL-C, ApoB, and raises HDL-C more than high-intensity statin monotherapy, though it is less effective at lowering triglycerides.
Who was in PCSK9 vs statin monotherapy meta-analysis?
20,369 people. Patients in RCTs of PCSK9i monotherapy (predominantly due to total statin intolerance) vs. patients in RCTs of high-intensity statin monotherapy; 5 trials (766 patients) for PCSK9is and 49 trials (19,603 patients) for statins; mean age 57.5±5.1 (PCSK9i) vs 60.2±2.3 (statin) years, women 54.3% vs 39.9%.
What was PCSK9 vs statin monotherapy meta-analysis's main result?
PCSK9is showed significantly greater reductions in LDL-C compared to all high-intensity statin regimens combined (-52.4% vs. -46.6%, p = 0.03)
How much did LDL cholesterol change in PCSK9 vs statin monotherapy meta-analysis?
PCSK9i: -52.4% vs. statins: -46.6% (p = 0.03)
Related trials
- CTT 2024 diabetes (2024)Statins cause a modest, dose-dependent increase in new-onset diabetes and worsening glycaemia, driven by small upward shifts in glucose/HbA1c, but this risk is already outweighed by the overall cardiovascular benefit of statin therapy.
- CTT 2022 muscle (2022)Statins cause a small, mostly mild excess of muscle pain primarily in the first year of treatment, with over 90% of muscle symptom reports in statin users not actually due to the statin, and this risk is far outweighed by cardiovascular benefits.
- PCSK9/ezetimibe diabetes meta-analysis (2020)Neither PCSK9 inhibitors nor ezetimibe increase the risk of new-onset diabetes when added to guideline-directed medical therapy.
- CTT 2019 older people (2019)Statins reduce major vascular events across all age groups including older people, though the evidence for benefit beyond age 75 without pre-existing vascular disease is less direct and being addressed by further trials.
Get your LDL treated to a goal
Preval Health's protocols follow trials like this one. Licensed clinicians set your goal, prescribe and recheck until you reach it.
Get startedEducation only, not medical advice. Results describe the people in this trial and can differ for you. Talk with your clinician before starting or stopping any medicine. Back to all 106 trials.